<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00111579</url>
  </required_header>
  <id_info>
    <org_study_id>MI-CP123</org_study_id>
    <nct_id>NCT00111579</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Immune Responses of Trivalent Cold-Adapted Influenza Vaccine (CAIV-T) Compared With (TIV)</brief_title>
  <official_title>A Prospective, Randomized, Open-Label Study to Evaluate the Immune Responses of Trivalent Cold-Adapted Influenza Vaccine (CAIV-T) Compared With Trivalent Inactivated Vaccine (TIV) in Children 6 to &lt;36 Months of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedImmune LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to describe the level of serum antibody conferred by CAIV-T and
      TIV against homotypic and heterotypic influenza virus strains.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2005</start_date>
  <completion_date type="Actual">January 2006</completion_date>
  <primary_completion_date type="Actual">January 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The following immunogenicity endpoints: The strain-specific HAI seroconversion rates (≥ 4-fold increase) among baseline seronegative participants (HAI titer ≤ 1:4), by dose number</measure>
    <time_frame>Day 28 post final vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The proportion of participants achieving ≥ 4-fold increase in strain-specific HAI titer from baseline in all participants regardless of baseline serostatus, by dose number</measure>
    <time_frame>Day 28 post final vaccination</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety endpoints include: AEs SAEs and significant new medical conditions for all participants</measure>
    <time_frame>Day 28 post vaccination</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment>52</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CAIV-T</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>TIV</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CAIV-T</intervention_name>
    <description>A total vol. of 0.2 mL will be administered intranasally (approx. 0.1 mL into each nostril)for ea. of two doses.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>TIV</intervention_name>
    <description>A total vol. of 0.25 will be administered intramuscularly for each of two doeses.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or Female

          -  Ages 6 to but less than 36 months (reached their 6th month but have not yet reached
             their 3rd birthday) at the time of randomization

          -  Written informed consent and Health Insurance Portability and Accountability Act
             (HIPAA) authorization (if applicable) obtained from the participant's parent/legal
             representative

          -  Ability of the parent/legal representative to understand and comply with the
             requirements of the study

          -  Parent/legal representative available by telephone

          -  Ability to complete follow-up period of 180 days after final study vaccination, as
             required by the protocol

        Exclusion Criteria:

          -  History of hypersensitivity to any component of CAIV-T or TIV, including egg or egg
             products, monosodium glutamate, porcine gelatin or thimerosal

          -  History of hypersensitivity to gentamicin

          -  Any known immunosuppressive condition or immune deficiency disease (including HIV
             infection), or ongoing receipt of any immunosuppressive therapy

          -  Household contact who is immunocompromised (participants should also avoid close
             contact with immunocompromised individuals for at least 21 days after each study
             vaccination)

          -  History of Guillain-Barre syndrome

          -  Medically diagnosed wheezing, bronchodilator use, or steroid use (systemic or
             inhaled), by parent/legal representative report or chart review, within the 42 days
             prior to randomization (i.e., children with recent persistent asthma are excluded); or
             history of severe persistent asthma, according to the criteria described in the
             National Asthma Education and Prevention Program (NAEPP) Expert Panel Report:
             Guidelines for the Diagnosis and Management of Asthma - Update on Selected Topics 2002

          -  Acute febrile (not greater than 100.0 degrees F oral or equivalent) and/or clinically
             significant respiratory illness (e.g., cough or sore throat) within 72 hours prior to
             either study vaccination

          -  Use of aspirin or aspirin-containing products within 30 days prior to randomization,
             or expected use through 180 days after final study vaccination

          -  Receipt of any prior influenza vaccine

          -  Use of anti-influenza medications (including amantadine, rimantadine, oseltamivir, and
             zanamivir) within 14 days prior to randomization, or expected use through 180 days
             after final study vaccination

          -  Administration of any live virus vaccine within 30 days prior to randomization, or
             expected receipt through 30 days after final study vaccination

          -  Administration of any inactivated (i.e., non-live) vaccine within 14 days prior to
             randomization, or expected receipt within 14 days before, or 14 days after, either
             study vaccination

          -  Receipt of any investigational agent within 30 days prior to randomization, or
             expected receipt through 180 days after final study vaccination (use of licensed
             agents for indications not listed in the package insert is permitted)

          -  Receipt of any blood product within 90 days prior to randomization, or expected
             receipt through 180 days after final study vaccination

          -  Family member or household contact who is an employee of the research center or
             otherwise involved with the conduct of the study

          -  Any condition that, in the opinion of the investigator, would interfere with
             evaluation of the vaccine or interpretation of the study results
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>36 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Walker, MD</last_name>
    <role>Study Director</role>
    <affiliation>MedImmune LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wee Care Pediatrics</name>
      <address>
        <city>Layton</city>
        <state>Utah</state>
        <zip>84041</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bear Care Pediatrics</name>
      <address>
        <city>Ogden</city>
        <state>Utah</state>
        <zip>84405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alpine Pediatrics</name>
      <address>
        <city>Pleasant Grove</city>
        <state>Utah</state>
        <zip>84062</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Utah Valley Pediatrics</name>
      <address>
        <city>Provo</city>
        <state>Utah</state>
        <zip>84604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Families First Pediatrics</name>
      <address>
        <city>South Jordan</city>
        <state>Utah</state>
        <zip>84095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 23, 2005</study_first_submitted>
  <study_first_submitted_qc>May 23, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 24, 2005</study_first_posted>
  <last_update_submitted>July 22, 2008</last_update_submitted>
  <last_update_submitted_qc>July 22, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 24, 2008</last_update_posted>
  <responsible_party>
    <name_title>Chris Ambrose, Dir. Medical Affairs</name_title>
    <organization>MedImmune LLC</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

